Economy/Home · Economy

HLB Group Stocks Mixed in Early Trading... HLB Rises 1% While HLB Global and HLB Panjin Plunge Double Digits

HLB group stocks showed mixed movements in early trading on the 12th. HLB's main stock is posting modest gains, but HLB Global and HLB Panjin are recording double-digit declines, highlighting clear differentiation among the group's affiliates. ■ Stock prices as of 9:32 a.m. - HLB: Up 1.20% from th

Oseong Kwon
Staff Reporter
4 min read
HLB Group Stocks Mixed in Early Trading... HLB Rises 1% While HLB Global and HLB Panjin Plunge Double Digits
CBC News

HLB group stocks showed mixed movements in early trading on the 12th. HLB's main stock is posting modest gains, but HLB Global and HLB Panjin are recording double-digit declines, highlighting clear differentiation among the group's affiliates.

■ Stock prices as of 9:32 a.m.

  • HLB: Up 1.20% from the previous trading day at 46,200 won
  • HLB Pharmaceutical: Down 2.13% at 12,850 won
  • HLB Life Science: Down 3.20% at 4,375 won
  • HLB Innovation: Down 4.40% at 17,790 won
  • HLB Therapeutics: Down 4.88% at 3,020 won
  • HLB Global: Down sharply 11.76% at 2,325 won
  • HLB Panjin: Down 12.57% at 1,551 won
  • HLB PHM: Down 4.31% at 4,995 won
  • HLB Biostep: Up 0.63% at 6,350 won

Of the nine group stocks, only two—HLB and HLB Biostep—rose, while seven declined, indicating that selling pressure was relatively dominant in early trading.

■ Resubmission for FDA Approval a Key Factor for Share Price Going Forward

Meanwhile, HLB recently announced that it had submitted a resubmission for new drug approval to the U.S. Food and Drug Administration (FDA) through its U.S. subsidiary Elevar Therapeutics for the combination therapy of rivoceranib and camrelizumab as a first-line treatment for liver cancer. This filing is a step to respond to the Complete Response Letter (CRL) received from the FDA in July.

After receiving the submission, the FDA classifies the review type, with Class 1 receiving a two-month review period and Class 2 receiving a six-month review period. Accordingly, attention is focused on how the FDA's review schedule and approval decision will affect the share prices of HLB and related group stocks. However, with wide gaps in gains and losses among the group's stocks during the day, it is necessary to also monitor intraday supply and demand changes and share price movements.

[※ This article is intended to convey market trends and is not intended to recommend investment in any specific stock.]

Oseong Kwon
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.